GAITHERSBURG, Md., Oct. 28, 2022 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced two scientific I announced that I will make a presentation at the conference.
- American Heart Association Science Session 2022, Chicago, IL
Saturday, November 5, 2022
Poster Presentation at 11:00 AM Central Time
Title: Effect of Pembijutide (ALT-801), a Novel GLP-1/Glucagon Dual Receptor Agonist, on Pathogenic Lipid Mediators
First Author: Jorge Plutzky, MD, Director, Preventive Cardiology, Brigham and Women’s Hospital
- American Liver Society, The Liver Meeting®Washington D.C.
Monday, November 7, 2022
Poster presentation at 1:00 p.m. ET
Title: Effects of a Balanced GLP-1/Glucagon Receptor Dual Agonist on Hepatic Fat Reduction and Weight Loss: Results of a Phase 1b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial in Patients with Non-Alcoholic Fatty Liver Disease
First author: Stephen A. Harrison, MD, Medical Director, Pinnacle Research
Copies of the presentation materials can be accessed from the Events section of the Altimmune website.
About Ultimune
Altimmune is a clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for the treatment of obesity and liver disease. The company’s lead product candidate, pembidutide, is his GLP-1/glucagon dual receptor agonist being developed for the treatment of obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is developing his HepTcell™, an immunotherapy designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. LinkedIn
Follow @AltimmuneInc twitter
Ultimune Investor and Media Contacts:
Richard Eisenstaedt
CFO
Phone: 240-654-1450
reisenstadt@altimmune.com
